We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Subcutaneous Blinatumomab in Relapsed/Refractory B-ALL: Clinical Promise and the Future of Delivery Modalities

MedXY Editorial Team•Oct 1, 2025•Clinical Updates
B-cell ALLblinatumomabimmunotherapysubcutaneous administration

Highlights

  • Subcutaneous blinatumomab achieved high remission rates (75-79%) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
  • Both evaluated dosing regimens exhibited manageable safety profiles, with primary toxicities consistent with known blinatumomab effects.
  • The 250 μg/500 μg subcutaneous regimen was selected as the recommended phase 2 dose due to balanced efficacy and tolerability.
  • Subcutaneous administration offers logistical and potentially economic advantages that may drive a future trend in immunotherapy delivery.

Clinical Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaA phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.Sep 6, 2026Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple MyelomaMezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.Sep 3, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Dual HLA-Restricted TCR-Engineered T Cells Targeting Cathepsin G: A Novel Approach for Effective AML Eradication
This study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.
Aug 25, 2026
Engineering High-Avidity Cathepsin-G-Specific CAR T Cells: A Promising Therapeutic Strategy for Acute Myeloid LeukemiaThis article reviews the development of high-avidity cathepsin-G-specific CAR T cells engineered with enhanced functional features to selectively target acute myeloid leukemia without hematopoietic toxicity, highlighting their preclinical eAug 23, 2026
Gut Microbiota and Metabolomic Signatures as Predictors of Immunotherapy Outcomes in MASLD and Viral HCCDistinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.Aug 22, 2026